文献速递类风湿关节炎

托法替布类风湿关节炎临床开发项目中的淋巴瘤分析

Lymphoma in the Tofacitinib Rheumatoid Arthritis Clinical Development Program.
PubMed 文献 · Arthritis Care Res (Hoboken) · 2018-04-02

该分析基于19项托法替布治疗中重度类风湿关节炎的临床研究,共6194例患者(19406患者年),观察到19例淋巴瘤,发生率0.10/100患者年,年龄性别调整后标准化发病比为2.62(95%CI 1.58-4.09),淋巴瘤发生率随时间稳定,病例与对照基线特征差异较小。

要点

  • 托法替布治疗RA患者淋巴瘤发生率为0.10/100患者年(95%CI 0.06-0.15),暴露时间延长未见发生率升高。
  • 年龄性别调整后淋巴瘤标准化发病比为2.62(95%CI 1.58-4.09),对照SEER数据库。
  • 淋巴瘤病例与匹配对照相比,干燥综合征病史、抗CCP抗体和类风湿因子阳性及平均糖皮质激素剂量较高。

核心结论

  • 在托法替布RA临床开发项目中,淋巴瘤发生率随时间保持稳定,淋巴瘤患者与无淋巴瘤患者的基线特征差异极小。

研究设计与样本

  • 基于19项托法替布治疗中重度RA的研究(2项I期、9项II期、6项III期、2项长期扩展),共6194例患者,托法替布剂量1-30 mg每日两次或20 mg每日一次,单药或联合传统合成DMARDs。

主要发现

  • 共观察到19例淋巴瘤,发生率0.10/100患者年(95%CI 0.06-0.15),未随暴露时间增加而升高。
  • 年龄性别调整后淋巴瘤标准化发病比为2.62(95%CI 1.58-4.09),参照SEER数据库。
  • 19例淋巴瘤的临床特征符合RA人群典型表现;3例EB病毒阳性,8例阴性,2例不确定,6例未检测。
  • 与匹配对照相比,淋巴瘤病例中干燥综合征病史、基线抗CCP抗体阳性和类风湿因子阳性的比例数值上更高。
  • 淋巴瘤病例的平均糖皮质激素剂量高于对照。

临床怎么用

  • 托法替布治疗RA时淋巴瘤发生率较低且随时间稳定,但仍需关注年龄性别调整后SIR升高(2.62)的信号。
  • 对合并干燥综合征、抗CCP抗体或类风湿因子阳性、以及使用较高剂量糖皮质激素的患者,应保持淋巴瘤监测意识。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Tofacitinib is an oral JAK inhibitor indicated for the treatment of rheumatoid arthritis (RA). We characterized lymphoma events in the tofacitinib RA clinical development program. METHODS: Lymphoma events (up to March 2015) were identified from 19 tofacitinib studies (2 phase I, 9 phase II, 6 phase III, and 2 long-term extension) of patients with moderate to severe RA. Patients in these studies received tofacitinib dosed at 1-30 mg twice daily or 20 mg once daily, as monotherapy or with conventional synthetic disease-modifying antirheumatic drugs. Lymphoma incidence rates (IRs; number of patients with events/100 patient-years) and standardized incidence ratios (SIRs) were calculated. A descriptive case-matched control analysis (1:4) was performed to identify potential risk factors for lymphoma. RESULTS: A total of 6,194 patients received tofacitinib (19,406 patient-years of exposure, 3.4 years median treatment duration). Nineteen lymphomas occurred (IR 0.10 [95% confidence interval (95% CI) 0.06-0.15]), with no increase observed with time of exposure. The age- and sex-adjusted SIR of lymphoma was 2.62 (95% CI 1.58-4.09) (Surveillance, Epidemiology, and End Results [SEER] program database). The clinical characteristics of the 19 lymphomas were typical for the RA population. Three lymphomas were positive for Epstein-Barr virus, 8 were negative, 2 were equivocal, and 6 were untested. Numerically, more lymphoma cases had a history of Sjögren's syndrome and were positive for anti-cyclic citrullinated protein and rheumatoid factor at baseline versus matched controls. The mean corticosteroid dose was higher for lymphoma cases versus controls. CONCLUSION: In the tofacitinib RA clinical development program, lymphoma rates were stable over time and there were minimal differences in the baseline characteristics of patients with and without lymphoma.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. Mariette X, Chen C, Biswas P, et al. Lymphoma in the Tofacitinib Rheumatoid Arthritis Clinical Development Program. Arthritis Care Res (Hoboken). 2018. PMID: 28941219. doi:10.1002/acr.23421

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。